L3VLUP
ProSign in

SRPT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SRPTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SRPT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSRPTVRTX
Q3 202011 holders, $3.1bn31 holders, $21.9bn
Q4 202013 holders, $4.0bn30 holders, $18.4bn
Q1 202111 holders, $1.3bn31 holders, $15.4bn
Q2 20219 holders, $1.0bn30 holders, $12.7bn
Q3 202110 holders, $1.2bn35 holders, $10.1bn
Q4 202113 holders, $1.2bn28 holders, $12.4bn
Q1 202212 holders, $1.1bn23 holders, $16.1bn
Q2 202213 holders, $946m25 holders, $18.1bn
Q3 202221 holders, $1.8bn22 holders, $18.4bn
Q4 202221 holders, $1.9bn28 holders, $18.4bn
Q1 202320 holders, $2.3bn26 holders, $21.4bn
Q2 202313 holders, $1.8bn27 holders, $24.7bn
Q3 202319 holders, $2.1bn33 holders, $24.3bn
Q4 202312 holders, $1.3bn32 holders, $28.6bn
Q1 202415 holders, $2.0bn31 holders, $29.8bn
Q2 202415 holders, $2.0bn29 holders, $33.4bn
Q3 202412 holders, $1.4bn27 holders, $33.5bn
Q4 20249 holders, $1.2bn26 holders, $28.5bn
Q1 202511 holders, $665m21 holders, $35.4bn
Q2 20255 holders, $175m21 holders, $32.3bn
Q3 20256 holders, $164m22 holders, $25.9bn
Q4 20257 holders, $298m26 holders, $31.8bn
Q1 20265 holders, $281m25 holders, $31.8bn
Q2 20265 holders, $132m26 holders, $34.6bn
SRPT

Sarepta Therapeutics Inc

Holders
6
Reported value
$164m
Buyers
2
Sellers
3

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SRPT (3)

PDT Partners LLC, Two Sigma Advisers LP, Two Sigma Investments LP

Only VRTX (19)

AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →